Cancer Immunology and Immunotherapy
Cancer Immunology and Immunotherapy

Author: Mansoor M. Amiji

Publisher: Academic Press

Published: 2021-08-18

Total Pages: 550

ISBN-13: 012823637X

DOWNLOAD EBOOK

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO

Engineering Technologies and Clinical Translation
Engineering Technologies and Clinical Translation

Author: Mansoor M. Amiji

Publisher: Academic Press

Published: 2021-08-25

Total Pages: 526

ISBN-13: 0323909507

DOWNLOAD EBOOK

Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies, focusing specifically on the development of solutions for drug delivery and its clinical outcomes. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses biomaterial, microfluidic, and biodegradable devices, engineered microbes, personalized medicine, clinical approval process, and many other IO technologies. Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Explores engineering technologies and their clinical translation in a comprehensive way - Presents forecasting on the future of nanotechnology and drug delivery for IO - Engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment
Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2016-11-10

Total Pages: 135

ISBN-13: 0309442354

DOWNLOAD EBOOK

Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune- Based Therapies and Developing Clinical Trials
Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune- Based Therapies and Developing Clinical Trials

Author: Jianxun Song

Publisher: Bentham Science Publishers

Published: 2015-04-16

Total Pages: 283

ISBN-13: 1681080486

DOWNLOAD EBOOK

Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively presents the methods which have been studied and used in cancer immunotherapy based on the different components of human immune system. The series will give clinicians and immunologists a roadmap of current trends in all branches of cancer immunology. This volume lists the major immune system components (such as T cells and NK cells and associated antigens/antibodies) which have been demonstrated to limit the growth of or kill tumor cells. Relevant applications in cancer therapy are also included in addition to a general introduction to engineered as well as targeted cancer immunotherapies (cancer vaccines).

Targeted Cancer Therapy in Biomedical Engineering
Targeted Cancer Therapy in Biomedical Engineering

Author: Rishabha Malviya

Publisher: Springer Nature

Published: 2023-04-11

Total Pages: 949

ISBN-13: 9811997861

DOWNLOAD EBOOK

This book highlights the role of Biomedical Engineering (BME) used in diagnosis (e.g., body scanners) and treatment (radiation therapy and minimal access surgery in order to prevent various diseases). In recent years, an important progress has been made in the expansion of biomedical microdevices which has a major role in diagnosis and therapy of cancer. When fighting cancer, efficacy and speed are of the utmost importance. A recently developed microfluidic chip has enabled a breakthrough in testing the efficacy of specialized cancer drugs. Effective cancer-targeting therapies will require both passive and active targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes. This book discusses the advancements and innovations in the field of BME that improve the diagnosis and treatment of cancer. This book is focused on bioengineering approaches to improve targeted delivery for cancer therapeutics, which include particles, targeting moieties, and stimuli-responsive drug release mechanisms. This book is a useful resource for students, researchers, and professionals in BME and medicine.

Systemic Drug Delivery Strategies
Systemic Drug Delivery Strategies

Author: Mansoor M. Amiji

Publisher: Academic Press

Published: 2021-08-21

Total Pages: 590

ISBN-13: 0323909256

DOWNLOAD EBOOK

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies. Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO

Targeted Cancer Immune Therapy
Targeted Cancer Immune Therapy

Author: Joseph Lustgarten

Publisher: Springer Science & Business Media

Published: 2009-10-09

Total Pages: 340

ISBN-13: 1441901701

DOWNLOAD EBOOK

Stimulation of the immune system’s ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.